These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37240587)

  • 21. Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies.
    Sankaranarayanan R; J Fleming E; J Garratt C
    Arrhythm Electrophysiol Rev; 2013 Apr; 2(1):36-40. PubMed ID: 26835038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype.
    Ellims AH; Iles LM; Ling LH; Chong B; Macciocca I; Slavin GS; Hare JL; Kaye DM; Marasco SF; McLean CA; James PA; du Sart D; Taylor AJ
    Eur Heart J Cardiovasc Imaging; 2014 Oct; 15(10):1108-16. PubMed ID: 24819852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?
    Nakano SJ; Menon SC
    Prog Pediatr Cardiol; 2018 Jun; 49():31-37. PubMed ID: 31097901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy.
    Sivalokanathan S
    Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Diagnosis of Thick Myocardium according to Histologic Features Revealed by Multiparametric Cardiac Magnetic Resonance Imaging.
    Cha MJ; Kim C; Park CH; Hong YJ; Shin JM; Kim TH; Cha YJ; Park CH
    Korean J Radiol; 2022 Jun; 23(6):581-597. PubMed ID: 35555885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease.
    Deva DP; Hanneman K; Li Q; Ng MY; Wasim S; Morel C; Iwanochko RM; Thavendiranathan P; Crean AM
    J Cardiovasc Magn Reson; 2016 Mar; 18():14. PubMed ID: 27036375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation across the spectrum of hypertrophic cardiac phenotypes.
    Lillo R; Graziani F; Franceschi F; Iannaccone G; Massetti M; Olivotto I; Crea F; Liuzzo G
    Heart Fail Rev; 2023 Sep; 28(5):1065-1075. PubMed ID: 37115472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of cardiac imaging in Anderson-Fabry cardiomyopathy.
    Serra W; Marziliano N
    Cardiovasc Ultrasound; 2019 Jan; 17(1):1. PubMed ID: 30674321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usefulness of cardiovascular magnetic resonance imaging in children with myocardial diseases.
    Ziółkowska L; Śpiewak M; Małek Ł; Boruc A; Kawalec W
    Kardiol Pol; 2015; 73(6):419-28. PubMed ID: 25563465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young.
    Österberg AW; Östman-Smith I; Jablonowski R; Carlsson M; Green H; Gunnarsson C; Liuba P; Fernlund E
    Pediatr Cardiol; 2021 Mar; 42(3):492-500. PubMed ID: 33515326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy: The STRAIN-HCM study.
    Negri F; Muser D; Driussi M; Sanna GD; Masè M; Cittar M; Poli S; De Bellis A; Fabris E; Puppato M; Grigoratos C; Todiere G; Aquaro GD; Sinagra G; Imazio M
    Int J Cardiol; 2021 Dec; 345():61-67. PubMed ID: 34728259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertrophic Cardiomyopathy and Primary Restrictive Cardiomyopathy: Similarities, Differences and Phenocopies.
    Vio R; Angelini A; Basso C; Cipriani A; Zorzi A; Melacini P; Thiene G; Rampazzo A; Corrado D; Calore C
    J Clin Med; 2021 May; 10(9):. PubMed ID: 34062949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of cardiac magnetic resonance-based markers in patients with hypertrophic cardiomyopathy.
    Dohy Z; Szabo L; Toth A; Czimbalmos C; Horvath R; Horvath V; Suhai FI; Geller L; Merkely B; Vago H
    Int J Cardiovasc Imaging; 2021 Jun; 37(6):2027-2036. PubMed ID: 33555536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms.
    Shariat M; Thavendiranathan P; Nguyen E; Wintersperger B; Paul N; Rakowski H; Crean AM
    J Cardiovasc Comput Tomogr; 2014; 8(6):429-37. PubMed ID: 25467830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study.
    Habib M; Adler A; Fardfini K; Hoss S; Hanneman K; Rowin EJ; Maron MS; Maron BJ; Rakowski H; Chan RH
    JACC Cardiovasc Imaging; 2021 May; 14(5):947-958. PubMed ID: 33248971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management.
    Baxi AJ; Restrepo CS; Vargas D; Marmol-Velez A; Ocazionez D; Murillo H
    Radiographics; 2016; 36(2):335-54. PubMed ID: 26963450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.
    Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF
    Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.